Radiation therapy boosts survival rates in recurrent prostate cancer patientsJune 18th, 2008 - 11:43 am ICT by ANI
Washington, June 18 (ANI): Researchers at the Johns Hopkins Medical Institutions have found that radiation treatment significantly increases the survival chances of relapsing prostate cancer patients.
Men whose tumors recur after prostate cancer surgery are three times more likely to survive their disease long term if they undergo radiotherapy within two years of the recurrence. Surprisingly, survival benefits were best in men whose new tumors were growing fastest, according to the “look-back” study of 635 men.
Previous studies of radiation therapy for recurrent prostate cancer found that it reduced disease progression, but this study demonstrates that it significantly prolongs survival, as well, according to Bruce J. Trock, Ph.D., associate professor of urology, epidemiology, oncology, and environmental health studies, and director of the Division of Epidemiology in the Brady Urological Institute at Johns Hopkins.
“What this new study tells us is that even men with aggressive disease that has recurred after surgery appear to benefit from radiation therapy. It also means that we may be able to give radiation selectively to those who are really likely to benefit from it,” said Trock.
“I found the results of this study remarkable,” said Patrick C. Walsh, M.D., University Distinguished Service Professor of Urology at the Brady Urological Institute.
“Previously, we believed that these men -who have aggressive disease defined by a rapid doubling of PSA in six months or less — had distant metastases and would not benefit from any form of local salvage therapy.”
PSA, or prostate specific antigen, is the blood-based protein shed by the organ that signals the likely presence of cancer. Rapid rises in PSA levels after surgical removal of the prostate signal the recurrence of cancer and often convey a poor prognosis.
Approximately 30 to 40 percent of men with high-risk tumors experience no recurrence of their cancers after surgery and can be spared the side-effects, that is, urinary and bowel problems, that may come with radiation.
So, the Johns Hopkins researchers were looking to determine whether radiation could improve survival in men with recurrent prostate cancer and the optimal timing for the therapy.
In the new study, the researchers reviewed records of 635 men who developed recurrent cancer following radical prostatectomy at Johns Hopkins Medical Institutions between June 1982 and August 2004. Of these, 397 received no salvage radiation therapy, 160 received only salvage radiation, and 78 received both salvage radiation and hormonal therapy. Median follow-up was six years after recurrence.
Among men who had received radiotherapy for prostate cancer recurrence, the probability of surviving 10 years was 86 percent, compared to 62 percent among those who did not have radiation. For patients with rapidly growing tumors, defined by a PSA doubling time of less than six months, the benefits of salvage radiation therapy existed regardless of Gleason score, a numerical value that measures prostate cancer aggressiveness.
“This review suggests that even patients with aggressive cancer at the time of surgery not only benefit from salvage radiation therapy, but also actually live longer without a second prostate cancer recurrence,” said Theodore L. DeWeese, M.D., professor and chairman of the Department of Radiation Oncology and Molecular Radiation Sciences.
“This is the most important news for this group of patients in a long time.”
DeWeese suggests that radiation oncologists and urologists now consider salvage radiation therapy for a broader group of patients with recurrent prostate cancer following surgery.
The study is published June 18 in the Journal of the American Medical Association. (ANI)
- New method detects aggressive prostate cancer - Aug 09, 2012
- Aspirin reduces risk of cancer recurrence in prostate cancer patients - May 03, 2011
- MRI can help locate prostate cancer recurrence at extremely low PSA levels - Apr 30, 2011
- Surgery effective for aggressive prostate cancer patients - Sep 28, 2010
- PSA test more reliable in men taking prostate-shrinking drug - Dec 18, 2010
- Chemo-radiation combo may avert prostate cancer recurrence - Nov 05, 2009
- Now, test to predict aggressiveness of prostate cancer - Apr 20, 2010
- New test accurately detects aggressive prostate cancer - Apr 07, 2011
- Aspirin use 'cuts risk of death from prostate cancer by more than half' - Oct 26, 2010
- New tool opens alternate door to prostate cancer diagnosis - Apr 03, 2011
- Prostate cancer screening improves patients' quality of life - Oct 26, 2010
- Combining radiation therapy, chemo safely treats head and neck cancers - Nov 04, 2010
- Robot-assisted surgery to remove cancerous prostate glands is safe - Mar 24, 2011
- Change in PSA level poor predictor of prostate cancer - Feb 25, 2011
- Frequent CT scanning for testicular cancer linked to secondary cancers - Mar 31, 2011
Tags: aggressive disease, brady urological institute, distant metastases, environmental health studies, johns hopkins medical, johns hopkins medical institutions, patrick c walsh, poor prognosis, prostate cancer patients, prostate cancer surgery, prostate specific antigen, psa levels, radiation therapy, radiation treatment, recurrent prostate cancer, service professor, survival benefits, survival chances, survival rates, trock